iOnctura

iOnctura is a Swiss-based biopharmaceutical company founded in 2017. The company is dedicated to developing precision small molecules to combat neglected and hard-to-treat cancers. Their innovative treatments, including roginolisib and cambritaxestat, have entered mid-stage clinical development, offering new hope to patients and their families. iOnctura has recently secured a significant €80.00M Series B investment on 20 June 2024, attracting support from a notable group of investors including VI Partners, 3B Future Health Fund, European Innovation Council, MERL Ventures Fund, Syncona Investment Management, Schroders Capital, Inkef. With a focus on improving healthspans and changing patients' outlook, iOnctura is poised to make a substantial impact in the biotechnology, healthcare, and pharmaceutical industries.